Eicher Motors, the maker of Royal Enfield, posted a 12% rise in net profit for the March quarter of FY26. ...More

Eicher Motors, the maker of Royal Enfield, posted a 12% rise in net profit for the March quarter of FY26. The company's revenue also saw a 16% increase. Royal Enfield achieved its highest quarterly sales and surpassed one million units annually for the second year. VE Commercial Vehicles also reported strong sales growth. ...Less

Sun Pharma Q1 Results FY26: Sun Pharmaceutical Industries reported a 20% fall in Q1 consolidated net prof ...More

Sun Pharma Q1 Results FY26: Sun Pharmaceutical Industries reported a 20% fall in Q1 consolidated net profit, reaching Rs 2,278 crore. Despite this dip, revenue from operations increased by 10% to Rs 13,786 crore. Strong performance in the India market and growth in global innovative medicines sales, including the U.S. launch of LEQSELVI, contributed to the company's overall progress. ...Less

Sun Pharma Q1FY24 net profit fell 2% YoY to Rs 2023 crore due to exceptional items worth Rs 323 crore. Ho ...More

Sun Pharma Q1FY24 net profit fell 2% YoY to Rs 2023 crore due to exceptional items worth Rs 323 crore. However, excluding exceptional items, net profit for Q1FY24 grew 13.8% to Rs 2345 crore. Earnings for interest, tax, depreciation, and ammortisation (EBITDA) grew 15.5% to Rs 3332 crore in Q1. ...Less

Total revenue for the quarter grew 10.73 per cent YoY to Rs 10,761.76 crore compared with Rs 9,718.74 cro ...More

Total revenue for the quarter grew 10.73 per cent YoY to Rs 10,761.76 crore compared with Rs 9,718.74 crore in the corresponding quarter last year. The revenue also beat the ET NOW poll projection of Rs 10,425 crore. ...Less

Sun Pharma Q1 Results: Sun Pharma reported a 40% increase in consolidated net profit to Rs 2,836 crore, s ...More

Sun Pharma Q1 Results: Sun Pharma reported a 40% increase in consolidated net profit to Rs 2,836 crore, surpassing estimates of Rs 2,638 crore. Revenue rose 6% YoY to Rs 12,653 crore. EBITDA grew 8% YoY to Rs 3,608 crore with margins at 28.5%. India formulation sales reached Rs 4,144 crore, up 16%, constituting 33.1% of total sales. ...Less

The fall in the bottomline was partly due to certain one-time charges totalling Rs 323 crore. The company ...More

The fall in the bottomline was partly due to certain one-time charges totalling Rs 323 crore. The company also incurred a one-time transitional cost of Rs 51 crore on the relocation of Alchemee operations from California to New York. ...Less

Consolidated net profit is seen declining 1.4% YoY to Rs 2,033 crore. India’s largest pharmaceutical comp ...More

Consolidated net profit is seen declining 1.4% YoY to Rs 2,033 crore. India’s largest pharmaceutical company by market capitalization is scheduled to release its earnings on Thursday. ...Less

Analysts had projected the profit figure at Rs 905 crore. ...More

Analysts had projected the profit figure at Rs 905 crore. ...Less

Sun Pharma share price: Sun Pharmaceutical's shares declined following a reported 20% YoY drop in Q1FY26 ...More

Sun Pharma share price: Sun Pharmaceutical's shares declined following a reported 20% YoY drop in Q1FY26 net profit, despite a 10% increase in revenue. Brokerages offer mixed recommendations: Nuvama suggests 'Hold,' while Avendus upgrades to 'Add,' anticipating future gains from India formulations and innovative drugs. Motilal Oswal maintains a 'Buy' rating, citing a strong portfolio, but lowers the target price due to increased expenses. ...Less

An ET Now Poll had expected the drug maker to report a profit of Rs 1,030 crore in the quarter ...More

An ET Now Poll had expected the drug maker to report a profit of Rs 1,030 crore in the quarter ...Less

The company’s consolidated revenues in the quarter rose 28 per cent year-on-year to Rs 9,719 crore, which ...More

The company’s consolidated revenues in the quarter rose 28 per cent year-on-year to Rs 9,719 crore, which was sharply above analysts’ expectations. ...Less

Out of the 27 Nifty50 companies that have reported their quarterly numbers so far, 12 have reported resul ...More

Out of the 27 Nifty50 companies that have reported their quarterly numbers so far, 12 have reported results that beat Street expectations, seven fell short of meeting investor expectations. Two companies reported in-line results while the rest six came out with a mixed set of numbers. ...Less

Shares of ABM Knowledgeware (Rs 1.25 per share), MRF (Rs 144 per share), Praj Industries (Rs 2.7 per shar ...More

Shares of ABM Knowledgeware (Rs 1.25 per share), MRF (Rs 144 per share), Praj Industries (Rs 2.7 per share), Hawkins Cookers (Rs 60 per share) and TCI Express (Rs 2 per share) had announced final dividend. The stocks went ex-dividend on Wednesday. ...Less

Sun Pharma shares traded 2.78 per cent higher at Rs 482.25 after the announcement of its quarterly result ...More

Sun Pharma shares traded 2.78 per cent higher at Rs 482.25 after the announcement of its quarterly results. ...Less

Other income for the quarter surged to Rs 314.95 crore compared with Rs 119.88 crore in the year-ago quar ...More

Other income for the quarter surged to Rs 314.95 crore compared with Rs 119.88 crore in the year-ago quarter. ...Less

Adani Enterprises Q1 Results FY26: Adani Enterprises experienced a 45% profit drop in the first quarter, ...More

Adani Enterprises Q1 Results FY26: Adani Enterprises experienced a 45% profit drop in the first quarter, reaching Rs 976.48 crore. Revenue also decreased by 13.7% to Rs 21,961.20 crore. Lower trade volumes and index price volatility impacted performance. However, incubating businesses saw a 5% EBITDA increase, driven by Airports and Roads segments. Navi Mumbai Airport and other projects are expected to contribute to future EBITDA. ...Less

The company approved a final dividend of Rs 4 per equity share which will be subject to the approval of t ...More

The company approved a final dividend of Rs 4 per equity share which will be subject to the approval of the shareholders. The total dividend payout for FY23 is Rs 11.5 per share compared to Rs 10 per share for FY22. ...Less

The S&P BSE Sensex rallied as much as 355 points in intraday trade on Tuesday led by gains in auto, capit ...More

The S&P BSE Sensex rallied as much as 355 points in intraday trade on Tuesday led by gains in auto, capital goods and oil & gas sectors. ...Less

IDFC First Bank posted a strong Q3FY26 performance with net profit rising 48% to Rs 503 crore and NII up ...More

IDFC First Bank posted a strong Q3FY26 performance with net profit rising 48% to Rs 503 crore and NII up 12% year-on-year. Asset quality improved with lower gross NPAs, while loan growth remained broad-based. The bank saw steady momentum in credit cards and wealth management, supported by easing provisions. ...Less

"Investors will continue to watch global developments before committing more money to equities," as per a ...More

"Investors will continue to watch global developments before committing more money to equities," as per an IIFL report. ...Less

The stock was trading with minor gains at the opening time and hit the day's high of Rs 1,430.45 on the N ...More

The stock was trading with minor gains at the opening time and hit the day's high of Rs 1,430.45 on the NSE, up 0.84% over the Wednesday closing price. ...Less

Nomura maintains a buy rating on Macrotech Developers with a target price of Rs 1,600, citing strong Q2 p ...More

Nomura maintains a buy rating on Macrotech Developers with a target price of Rs 1,600, citing strong Q2 performance and anticipated 20% YoY pre-sales growth. For BPCL, Nomura raises the target to Rs 380 despite lower results. Nuvama and Jefferies also maintain buy ratings on Federal Bank (target Rs 235) and Sun Pharma (target Rs 2,150), respectively, highlighting strong performance and growth potential. ...Less

ITC is anticipated to reveal moderate revenue growth, driven by cigarettes and agri businesses, while Sun ...More

ITC is anticipated to reveal moderate revenue growth, driven by cigarettes and agri businesses, while Sun Pharma is expected to showcase high single-digit bottom-line growth, fueled by strong domestic performance. Revenue growth for Sun Pharma is expected to be 9% year-on-year, while ITC's revenue is expected to rise 2% year-on-year. Analysts anticipate $500 million in US sales for Sun Pharma. ...Less

The S&P BSE Sensex rallied nearly 400 points in intraday trade on Tuesday led by gains in auto, capital g ...More

The S&P BSE Sensex rallied nearly 400 points in intraday trade on Tuesday led by gains in auto, capital goods and oil & gas sectors. ...Less

Bharti Airtel Q2 Results: The company's revenue from operations for the quarter reached Rs 41,473 crore, ...More

Bharti Airtel Q2 Results: The company's revenue from operations for the quarter reached Rs 41,473 crore, marking a 12% increase from Rs 37,044 crore in the same quarter last year. The average revenue per user (ARPU) rose 15% year-on-year to Rs 233 from Rs 203 in Q2FY24. Consolidated net income (before exceptional items) increased by 32.2% YoY to Rs 3,911 crore. ...Less

The S&P BSE Sensex rallied as much as 266 points in intraday trade on Tuesday led by gains in auto, capit ...More

The S&P BSE Sensex rallied as much as 266 points in intraday trade on Tuesday led by gains in auto, capital goods and oil & gas sectors. ...Less

Revenue from operations is likely to jump 10% year-on-year, according to the average estimate of four bro ...More

Revenue from operations is likely to jump 10% year-on-year, according to the average estimate of four brokerages. Meanwhile, net profit for the quarter is projected to rise by up to 25% YoY. The pharma major will report its September quarter results on Monday, October 28. ...Less